Ismn Genericon

Isosorbide 5 Mononitrate, the active ingredient in Ismn Genericon, is a nitrate vasodilator presented as an oral dosage form for oral use. It is employed for the prevention of angina pectoris and the management of chronic stable angina in adult patients.

GNH USA supplies Ismn Genericon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ismn Genericon, a nitrate vasodilator, is indicated for conditions related to coronary artery disease and angina.

Angina pectoris (prevention): reduces the frequency of anginal episodes. Chronic stable angina: improves exercise tolerance and reduces symptom burden. Chest pain due to coronary artery disease: provides prophylactic relief of ischemic discomfort.

Ismn Genericon may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate, often transient. - Dizziness or light‑headedness: related to blood pressure reduction. - Flushing: warm sensation, especially after the first dose. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Syncope: fainting episodes due to sudden vasodilation. - Allergic reactions: rash, itching, or anaphylaxis in rare cases.

Before initiating therapy, clinicians should evaluate cardiovascular status and consider potential contraindications.

Assess blood pressure: ensure baseline values are adequate before starting. Review concomitant nitrate use: avoid additive vasodilatory effects. Monitor for hypotension: advise patients to rise slowly from sitting or lying positions. Avoid use with phosphodiesterase‑5 inhibitors: risk of severe blood pressure fall. Store at room temperature: keep in the original container, protect from moisture and heat.

Ismn Genericon can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other nitrates (e.g., nitroglycerin): additive vasodilation may cause profound hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of severe blood pressure reduction. - Alcohol: can potentiate hypotensive effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (e.g., ACE inhibitors, beta‑blockers): may require dose adjustment. - Diuretics: combined effect on blood pressure may need monitoring. - Antiplatelet drugs: monitor for increased bleeding tendency.